References
- Weber CR, Turner JR. Inflammatory bowel disease: is it really just another break in the wall? Gut 2007;56: 6–8
- Hollander D. Crohn's disease—a permeability disorder of the tight junction? Gut 1998;29: 1621–4
- Uko V, Thangada S, Radhakrishnan K. Liver disorders in inflammatory bowel disease. Gastroenterol Res Practice 2012;2012: 642923
- Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis 2010;16: 1598–619
- Greenstein AJ, Janowitz HD, Sachar DB. The extra intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine 1976;55: 401–12
- Riegler G, D'Incà R, Sturniolo GC, et al. Hepatobiliary alterations in patients with inflammatory bowel disease: a multicenter study. Caprilli & Gruppo Italiano Studio Colon-Retto. Scand J Gastroenterol 1998;33: 93–8
- Miehsler W, Reinisch W, Valic E, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 2004;53: 542–8
- Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 2006;12: 4819–31
- Martin E, Ramsay G, Mantz J, Sun-Ping ST. The role of the α2-adrenoceptor agonist dexmedetomidine in postsurgical sedation in the intensive care unit. J Intensive Care Med 2003;18: 29–41
- Mantz J, Josserand J, Hamada S. Dexmedetomidine: new insights. Eur J Anesthesiol 2011;28: 3–6
- Dere K, Sucullu I, Budak ET, et al. A comparison of dexmedetomidine versus midazolam for sedation, pain and hemodynamic control, during colonoscopy under conscious sedation. Eur J Anesthesiol 2010;27: 648–52
- Memis D, Hekimoglu S, Vatan I, et al. Effects of midazolam and dexmedetomidine on inflammatory response and gastric intramucosal pH to sepsisin critically ill patients. Br J Anesthesia 2007;98: 550
- Panzer O, Moitra V, Sladen RN. Pharmacology of sedative analgesic agents: dexmedetomidine, remifentanil, ketamine, volatile anesthetics, and the role of peripheral mu antagonists. Crit Care Clin 2009;25: 451–69
- Aharoni R, Kayhan B, Brenner O, et al. Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease. J Pharmacol Exp Ther 2006;18: 68–78
- Buege AJ, Aust SD. Microsomal lipid peroxidation. Methods Enzymol 1978;52: 302–10
- Sun Y, Oberley LW, Li Y. A simple method for clinical assay of superoxide dismutase. Clin Chem 1988;34: 497–500
- Lawrence RA, Burk RF. Glutathione peroxidase activity in selenium-deficient rat liver. Biochem Biophys Res Commun 1976;71: 952–8
- Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193: 265–75
- Masubuchi Y, Enoki K, Horie T. Down-regulation of hepatic cytochrome P450 enzymes in rats with trinitrobenzene sulfonic acid-induced colitis. Drug Metab Dispos 2008;36: 597–603
- Taniguchi T, Kidani Y, Kanakura H, et al. Effects of dexmedetomidine on mortality rate and inflammatory responses to endotoxin-induced shock in rats. Crit Care Med 2004;32: 1322–6
- Sezer A, Memis D, Usta U, Sut N. The effect of dexmedetomidine on liver histopathology in a rat sepsis model: an experimental pilot study. Turkish J Trauma Emerg Surg 2010;16: 108–12
- Hancı V, Erol B, Bektas S, Mungan G, et al. Effect of dexmedetomidine on testicular torsion/detorsion damage in rats. Urol Int 2010;84: 105–11
- Ayoglu H, Gul S, Hancı V, et al. The effects of dexmedetomidine dosage on cerebral vasospasm in a rat subarachnoid haemorrhage model. J Clin Neurosci 2010;17: 770–3
- Eser O, Fidan H, Sahin O, et al. The influence of dexmedetomidine on ischemic rat hippocampus. Brain Res 2008;1218: 250–6